Patent Filing. At SPONSOR’s request and expense, UNIVERSITY will file patent applications in the United States and in foreign countries for UNIVERSITY or Joint Inventions. For Joint Inventions, SPONSOR may, with UNIVERSITY approval, control the patent application filing, prosecution and maintenance. SPONSOR will make any filing request to UNIVERSITY in writing and within 60 days of UNIVERSITY’s notice of Invention disclosure. UNIVERSITY will keep SPONSOR promptly informed regarding the status of any patent application filed at SPONSOR’s expense and will give SPONSOR reasonable opportunity to comment. If SPONSOR elects not to have UNIVERSITY file patent applications, then UNIVERSITY may, at its discretion and at its expense, file patent applications in the United States and in foreign countries for any UNIVERSITY or Joint Invention.
Patent Filing. The Collaborator responsible for filing any Patent Application for a Subject Invention shall notify the other Collaborator of all filing deadlines for prosecution of any Patent Application and maintenance of any Patents on the Subject Invention. Notwithstanding the primary responsibility defined in Article 7.10, sixty (60) days prior to any filing deadline, the Collaborators shall confer to determine if the filing Collaborator intends to respond to the filing deadline. The non-filing Collaborator has the right to take action if the filing Collaborator declines.
Patent Filing. During the term of this Agreement, with respect to any ------------- Patent Rights or Inventions licensed hereunder:
Patent Filing. During the Term of this Agreement, with respect to any Patent Rights of Licensed Products arising hereunder:
Patent Filing. During the Term and thereafter during any period of time during which WCCI shall have a license under this Agreement to Paratek Patent Rights or to Joint Patent Rights, with respect to any Patent Rights arising hereunder:
Patent Filing. Intel may, in its sole discretion, file patent applications claiming the Patent Rights for Inventions in the LiDAR Transitional Technology and may file anywhere in the world, solely in its own name, and at its own expense. Intel need not file any patent application for any such Invention and need not maintain any patent application it has filed.
Patent Filing. (a) CURAGEN shall have the responsibility to prepare, file, prosecute, obtain and maintain U.S. and foreign patent applications and patents on Inventions at its sole expense. Initial patent filings shall be made in the form of a regular CFR Rule 1.51 U.S. Priority patent application or a provisional application, as determined by the Patent Coordinators. The Patent Coordinators for each Party will be designated by such Party from time to time. Patent applications will be perfected by making, as soon as available, an ATCC deposit of at least such Clone(s) as reasonably agreed by the Patent Coordinators, and by making any subsequent application filings necessary to perfect U.S. or foreign priority patent rights in the countries of Europe that are members of the European Patent Organization, Japan, Canada, Mexico and at least such other countries as mutually agreed by the Parties. GENENTECH agrees to provide reasonable and timely assistance and cooperation to CURAGEN to facilitate such filing, prosecution and maintenance, including without limitation, the execution of appropriate powers of attorney. CURAGEN agrees that any such preparation, filing, prosecution and maintenance shall be conducted diligently and in a timely fashion. GENENTECH shall be kept fully informed by CURAGEN of the progress of all patent filings and prosecution hereunder and shall be provided with copies of all material documents pertaining thereto including, without limitation, information regarding inventorship, sequences and sequence listings, serial numbers, filing dates, foreign filing licenses and copies of patent applications, until the end of the Exclusive Evaluation Period, and for any Invention which becomes subject to an Option, until the end of the Option Period. GENENTECH shall be given the opportunity, whenever practical, to review and comment in advance on any patent filings or other correspondence with the patent office during such periods and CURAGEN shall use reasonable efforts to incorporate any comments provided by GENENTECH. CURAGEN shall pursue its priority to claims on Inventions by filing all necessary interferences and opposition papers, motions and the like. Any proposed interference settlement agreement relating to Inventions subject to potential Option by GENENTECH hereunder will be reviewed by the RC.
Patent Filing. [* * *].
Patent Filing. (a) CURAGEN shall have the first right (but not the obligation) to prepare, file, prosecute, obtain and maintain patent applications and patents on Inventions, at its sole expense. BIOGEN agrees to provide reasonable assistance and cooperation to CURAGEN to facilitate such filing, prosecution and maintenance. CURAGEN agrees that any such preparation, filing, prosecution and maintenance shall be conducted diligently and that BIOGEN shall be kept fully informed of the progress thereof and provided with copies of all material documents pertaining thereto until the end of the Exclusive Evaluation Period, and for any Invention which becomes subject to an Option, until the end of the Option Period. BIOGEN shall, whenever possible, be given the opportunity to review and comment in advance on any patent filings or other correspondence with the patent office during such periods and CURAGEN shall consider incorporating any comments provided by BIOGEN in good faith.
Patent Filing. Elevance hereby consents to Clariant making a patent filing based on Clariant’s evaluation of the Sample in the Field solely with respect to the Permitted Claims. Prior to making any patent filing, Clariant shall disclose to Elevance the patent application comprising the Permitted Claims in order to permit Elevance to verify that the patent application is limited to the Permitted Claims and to give Elevance a reasonable opportunity to review and comment on such application. Elevance shall treat such applications and related documents as Confidential Information, except for such information in such applications and related documents that was known to Elevance prior to disclosure by Clariant and provided that any such information that is subsequently disclosed in a published patent application shall ceases to be Confidential Information. Clariant shall not make any patent application filing with respect to the Permitted Claims (whether an initial application, a subsequent application, any foreign counterpart application, or otherwise) without first obtaining the prior written consent of Elevance, such consent not to be unreasonably withheld, conditioned, or delayed. The Parties shall coordinate and cooperate in good faith to identify the data, technical information and other details necessary to support Clariant’s patent application with respect to the Permitted Claims. Clariant shall make a patent filing with respect to the Permitted Claims no later than three (3) weeks after the Effective Date of this Agreement. For the avoidance of doubt, Clariant may disclose certain information related to and limited to the evaluation of the Sample solely as necessary to seek patent protection for Permitted Claims included in a patent application, in which case such information shall no longer be deemed Confidential Information.
